Technical Analyst Rajesh Jain of SMC Global has maintained 'buy' rating on Sun Pharmaceutical Industries Limited stock to achieve a target of Rs 1680 in 2-4 weeks.

According to analyst, investors can buy the stock with a stop loss of Rs 1500.

Today (May 14), the shares of the company opened at Rs 1572.05 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 1846 and a low of Rs 1103 on BSE.

Current EPS & P/E ratio stood at 65.25 and 24.40 respectively.

Sun Pharmaceutical, on May 06, announced that its division has bagged USFDA nod for its Abbreviated New Drug Application (ANDA) to sell a generic edition of Forest Laboratories, Inc.` s Namenda in the potencies of 5 mg and 10 mg.

Sun was amongst the first ANDA appliers to forward a substantially complete ANDA with a paragraph IV certification to the `703 patent. Sun`s arm is entitled for 180 days generic exclusivity.

Sun Pharmaceutical is a global pharma company, which manufactures generic and brand name medications distributed in the United States, Europe, Asia and worldwide.

The products of the company, which makes both pharmaceuticals and API, are in various therapeutic regions, neurology, cardiology, diabetology, gastroenterology, respiratory, and orthopedics.